Teri Loxam
Known title: DirectorCIK: 0001829111
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Compass Pathways Q2 2026 Earnings Released Amid Low RSI. Compass Pathways has released its Q2 2026 results, providing the latest financial update for the company. The news cycle also includes broader sector commentary on pipeline risks, though specific details for Compass remain focused on the earnings release. The stock is currently trading near its 52-week low, reflecting recent market sentiment.
Transaction History
| PCVX | ▲ Buy | Grant | 2,265 | $0 | 6/15/2026 | View on chart |
| CMPS | ▲ Buy | Grant | 75,000 | $0 | 3/26/2026 | View on chart |
| CMPS | ▼ Sell | Tax Withholding | 1,781 | $12K | 3/11/2026 | View on chart |
| CMPS | ▼ Sell | Tax Withholding | 4,467 | $31K | 3/2/2026 | View on chart |
| PCVX | ▲ Buy | Grant | 3,041 | $0 | 6/12/2025 | View on chart |
| CMPS | ▲ Buy | Grant | 25,000 | $0 | 3/11/2025 | View on chart |
| CMPS | ▼ Sell | Tax Withholding | 4,468 | $16K | 3/3/2025 | View on chart |
| PCVX | ▲ Buy | Option Exercise | 6,250 | $142K | 1/15/2025 | View on chart |
| PCVX | ▼ Sell | Open Market | 146 | $12K | 1/15/2025 | View on chart |
| PCVX | ▼ Sell | Open Market | 215 | $18K | 1/15/2025 | View on chart |
| PCVX | ▼ Sell | Open Market | 1,136 | $94K | 1/15/2025 | View on chart |
| PCVX | ▼ Sell | Open Market | 1,202 | $101K | 1/15/2025 | View on chart |
| PCVX | ▼ Sell | Open Market | 1,043 | $89K | 1/15/2025 | View on chart |
| PCVX | ▼ Sell | Open Market | 966 | $83K | 1/15/2025 | View on chart |
| PCVX | ▼ Sell | Open Market | 1,013 | $89K | 1/15/2025 | View on chart |
| PCVX | ▼ Sell | Open Market | 529 | $47K | 1/15/2025 | View on chart |
| PCVX | ▼ Sell | Open Market | 4,308 | $502K | 9/17/2024 | View on chart |
| PCVX | ▲ Buy | Option Exercise | 6,250 | $142K | 9/17/2024 | View on chart |
| PCVX | ▼ Sell | Open Market | 241 | $28K | 9/17/2024 | View on chart |
| PCVX | ▼ Sell | Open Market | 1,445 | $167K | 9/17/2024 | View on chart |
| PCVX | ▼ Sell | Open Market | 256 | $30K | 9/17/2024 | View on chart |
| PCVX | ▲ Buy | Grant | 1,550 | $0 | 6/6/2024 | View on chart |
| CMPS | ▲ Buy | Grant | 62,718 | $0 | 3/1/2024 | View on chart |
| PCVX | ▲ Buy | Grant | 2,500 | $0 | 6/13/2023 | View on chart |
| PCVX | ▲ Buy | Grant | 3,125 | $0 | 6/1/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Vaxcyte VAX-31 clears Phase III OPUS-1 trial endpoints
Vaxcyte announced that its VAX-31 vaccine met all primary endpoints in the pivotal Phase III OPUS-1 trial. This positive data point positions the company for additional readouts expected in the first half of 2027. The stock is currently trading near its 52-week high, reflecting strong market interest in the clinical progress.
Vaxcyte VAX-31 clears Phase III OPUS-1 trial endpoints. Vaxcyte announced that its VAX-31 vaccine met all primary endpoints in the pivotal Phase III OPUS-1 trial. This positive data point positions the company for additional readouts expected in the first half of 2027. The stock is currently trading near its 52-week high, reflecting strong market interest in the clinical progress.